Drugs / NP-G2-044
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03199586 | Dec 2017 → May 2020 | breast cancer, colorectal cancer, esophageal cancer, liver cancer +5 | Novita Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05023486 | Dec 2021 → Jun 2026 overdue | — | Novita Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07109414 | Dec 2025 → Oct 2028 expected | refractory malignant neoplasm | Novita Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP-G2-044 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05023486 ↗ |
| Modality | Small molecule | — CHEMBL4297473 ↗ |
| Route | Oral | “when given orally on a daily X 28 days” NCT03199586 ↗ |